Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Taurolidine in Treating Patients With Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
This study is ongoing, but not recruiting participants.
Study NCT00021034 Information provided by National Cancer Institute (NCI)
First Received: July 11, 2001 Last Updated: February 6, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Fallopian Tube Cancer
Ovarian Cancer
Peritoneal Cavity Cancer
Additional conditions recognized in this trial
Fallopian Tube Neoplasms
Ovarian Neoplasms
Peritoneal Neoplasms
More general conditions related to this trial
Abdominal Neoplasms
Adnexal Diseases
Digestive System Diseases
Digestive System Neoplasms
Endocrine Gland Neoplasms
Endocrine System Diseases
Fallopian Tube Diseases
Genital Diseases, Female
Genital Neoplasms, Female
Gonadal Disorders
Neoplasms
Neoplasms by Site
Ovarian Diseases
Peritoneal Diseases
Urogenital Neoplasms
Interventions listed in this trial
chemotherapy
taurolidine
More general drug interventions related to this trial
Anti-Infective Agents
Anti-Infective Agents, Local
Antineoplastic Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Memorial Sloan-Kettering Cancer Center
National Cancer Institute (NCI)
Back to top of Main Content
